http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Solana Memecoin $SON is First-Ever Meme to Utilize New Payment Flow with Moonpay & Moongate
-
Solana Memecoin $SON is First-Ever Meme to Utilize New Payment Flow with Moonpay & Moongate
-
Dreame Technology Revolutionizes Home Cleaning with the Aqua10 Ultra Roller -- the World's First AquaRoll™ Mopping Robot Vacuum
-
Entera Bio presents oral GLP-2 tablet data at medical conference
-
Slope Software Chosen to Present at Venture Atlanta 2025, the Southeast's Premier Tech Conference
-
ADHC Announces First Digital Asset Treasury Purchase With Acquisition of Solana Based OTCfi Tokens
-
CPKC joins forces to promote rail safety across North America
-
Hungry Howie's Brings Detroit-Style Pizza Nationwide, Honoring its Detroit Roots
-
Suffolk Breaks Ground as Design-Build Partner for Miami-Dade County’s Lightspeed Emergency Operations Center
-
Planet Classroom & VoiceAmerica Launch Podcast: AI for a Better World - Human Creativity: Our Edge in the AI Era
-
Mercantile Bank Selects Jack Henry for Focus on Innovation and Growth
-
HomeServe Reminder: September 25 is National Fall Tune-Up Day
-
Pega Announces Quarterly Cash Dividend for Fourth Quarter of 2025
-
New U.S. Green Building Council Guide Showcases LEED as a Catalyst for Sustainable Finance
-
More Perfect & iCivics Announce Major Commitments To Fund Civic Learning & Service Programs
-
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
-
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
-
Employee Fiduciary Urges DOL to Reject PEP Safe Harbor in Favor of a Higher-Standard, Lower-Cost Path for Small Businesses
-
Research Frontiers aerospace VP Michael LaPointe retires after 31 years
-
Advisor Insights Help Plan Sponsors Simplify Complexity, According to 16TH Fidelity® Plan Sponsor Attitudes Study
-
BitMEX Launches Alpha Showdown Trading Competition: Win a 3 BTC Prize Pool and More
-
IMAX Slashes to $20 Million Global Weekend for “Demon Slayer: Infinity Castle” as Anime Phenomenon Expands to North America
-
AFSP Offers Resources and Learning to Fight Suicide in Hispanic & Latine Communities this Hispanic Heritage Month
-
RESEARCH FRONTIERS ANNOUNCES RETIREMENT OF MICHAEL R. LAPOINTE, WHO LED EXPANSION OF SPD-SMART AEROSPACE PROGRAMS
-
American Resources Corporation's ReElement Technologies Announces September Slate of Conferences and Events
-
Mothers Against Drunk Driving Marks 45th Anniversary in Washington, D.C. With Two Days of Innovation, Advocacy, and Remembrance
-
Helius raises over $500 million to launch Solana treasury strategy
-
Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company
-
Canalys Study Finds Every $1 of Falcon Platform Sales Leads Up to $7 in Partner Services Revenue
-
Rubrik expands CrowdStrike integration for identity threat rollback
-
Krystal Biotech receives FDA approval for expanded VYJUVEK label
-
USAFacts to Unveil 50-Foot Interactive Installation on the National Mall to Demonstrate Data’s Power to Clarify Today’s Political Headlines
-
Slate Grocery REIT Announces Distribution for the Month of September 2025
-
Toshiba Innovation Moves Printer Registration to the Cloud
-
Rubrik Integrates With CrowdStrike Falcon® Next-Gen Identity Security to Deliver Rollback of Malicious Identity Changes
-
Versa Announces New Integrations with CrowdStrike Falcon Platform
-
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
-
Trailbreaker Resources Provides Corporate Update
-
Green Rain Energy Holdings Inc. (OTC: GREH) Expands EV Charging Vision with Innovative Equity & Community-Driven Model
-
Palvella Therapeutics completes enrollment in phase 2 trial for rare skin condition
-
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
-
First Phosphate Closes Follow-On Tranche of Oversubscribed Private Placement
-
MyGold Token Announces Global Presale Launch on GemPad, Targeting $300 Million With Gold-Backed Blockchain Innovation
-
XRP Tundra Details Dual-Token Model With On-Ledger Staking Up to 25% APY
-
NovoCure's Optune Lua receives approval in Japan for lung cancer treatment
-
Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
-
The Florida Aquarium and IUCN SSC Launch World’s First Center for Species Survival on Coral Conservation
-
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treate
-
New Butterball® Report Reveals 2025 Thanksgiving Plans
-
Pacific Ridge Announces Investor Relations Agreement
